Oral PAI-1 Inhibitor
Fibrosis and Fibroproliferative Diseases
PreclinicalActive
Key Facts
Indication
Fibrosis and Fibroproliferative Diseases
Phase
Preclinical
Status
Active
Company
About MDI Therapeutics
MDI Therapeutics is a private, preclinical-stage biotech focused on a novel approach to treating fibrosis by inhibiting PAI-1. The company's foundational science originates from the University of Michigan laboratory of its founder, Dr. Daniel A. Lawrence, a world-renowned expert in serpin biology. While its lead oral PAI-1 inhibitor program represents a first-in-class opportunity in a large, underserved market, the company appears to be in a quiet phase, with no active hiring and limited public updates on pipeline progression. Leadership combines deep scientific expertise with seasoned pharmaceutical development experience.
View full company profile